The 12 - week combination of SOF / DCV / RBV achieved a 100 % SVR4 rate in cirrhotic patients without the additive effect of extension of the treatment to 24 weeks with or without RBV (95.7 % and 92.5 %, respectively), and this was also true in experienced patients. (sciencedaily.com)
The study found that metformin reduced blood pressure in the liver, liver scarring and inflammation after one week of use in cirrhotic rats. (sciencedaily.com)
Phase III results revealed today at The International Liver Congress ™ 2015 show that once - daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97 % sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients. (sciencedaily.com)